Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 9/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 9/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 8/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 5/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | DRD1 | P21728 | 1/20 | 0.62 |
| ▸ | DRD5 | P21918 | 1/20 | 0.62 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194898 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8880201 | 0.98 | CHRM2 (0.96) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8881870 | 0.95 | CHRM2 (0.91) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8881344 | 0.95 | CHRM2 (0.90) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8881459 | 0.94 | CHRM2 (0.89) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8881253 | 0.93 | CHRM2 (0.86) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8880466 | 0.92 | CHRM2 (0.85) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8879988 | 0.92 | CHRM2 (0.85) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8881541 | 0.91 | CHRM2 (0.83) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8878832 | 0.91 | CHRM2 (0.83) | CHRM2CHRM1CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3646870-B1 | COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | PureTech Health LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260124147-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250339418-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12427149-B2 | Methods and compositions for the prevention and treatment of hearing loss | Ting Theropeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250268883-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12290513-B2 | Therapeutic methods and compositions for treating movement disorders | Vima Therapeutics, Inc. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250127786-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250000867-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS, INC (US) | 2025-01-02 | — | — | US | disclosed |
| US-20240366583-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2024-11-07 | — | — | US | disclosed |
| CN-118767143-A | Compositions and methods for preventing and treating hearing loss | 听治疗有限责任公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240016792-A1 | MUSCARINIC M2 RECEPTOR BLOCKADE TO DELAY OR PREVENT ONSET OF PROGRESSIVE MEMORY DECLINE | US GOV VETERANS AFFAIRS (US) | 2024-01-18 | — | — | US | disclosed |
| US-11801241-B2 | Muscarinic M2 receptor blockade to delay or prevent onset of progressive memory decline | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2023-10-31 | — | — | US | disclosed |
| US-20220348879-A1 | PLURIPOTENT STEM CELL, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | BEIJING INSTITUTE FOR STEM CELL AND REGENERATIVE MEDICINE (CN) | 2022-11-03 | — | — | US | disclosed |
| CN-113527172-B | M2 acetylcholine receptor antagonists and uses thereof | 上海交通大学医学院附属仁济医院 | 2022-10-25 | — | — | CN | disclosed |
| EP-4073102-A2 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | Ting Therapeutics LLC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-11433073-B2 | Compositions and methods for the prevention and treatment of hearing loss | TING THERAPEUTICS LLC (US) | 2022-09-06 | — | — | US | disclosed |
| CN-114981298-A | Compositions and methods for preventing and treating hearing loss | 听治疗有限责任公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220265660-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | TING THERAPEUTICS LLC (US) | 2022-08-25 | — | — | US | disclosed |
| EP-4047083-A1 | PLURIPOTENT STEM CELL, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Beijing Institute for Stem Cell and Regenerative Medicine (CN) | 2022-08-24 | — | — | EP | disclosed |
| US-20220133730-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS LLC (US) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268883-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM1 8/4885CHRM3 1/4885 |
| US-12290513-B2 | Therapeutic methods and compositions for treating movement disorders | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM1 8/4885CHRM3 1/4885 |
| US-20250339418-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM1 8/4885CHRM3 1/4885 |
| US-20260124147-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM5, CHRM4, CHRM2 | CHRM2 3/4885CHRM1 11/4885CHRM3 4/4885 |
| US-20240366583-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM3, CHRNA5, CHRNA7 | CHRM2 7/4885CHRM1 15/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.